BPC-157 (Oral) vs TB4-Frag (TBF)
A side-by-side research comparison of BPC-157 (Oral) and TB4-Frag (TBF) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | TB4-Frag (TBF) |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Thymosin Beta-4 Fragment |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | Retains the actin-sequestering motif of full TB-4, promoting cell migration, angiogenesis, and reduction of inflammation at injury sites. The shorter sequence may offer improved bioavailability and targeted tissue penetration. |
| Molecular weight | 1419.53 Da | ~1,200-1,800 Da (fragment) |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | ~2-4 hours |
| Bioavailability | ~40-60% oral (arginate salt form) | High subcutaneous absorption |
| Typical dose | 500 mcg - 1 mg | 200-750 mcg per dose |
| Frequency | 1-2x daily | Daily or every other day |
| Route | Oral capsule (arginate salt) | Subcutaneous injection |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
TB4-Frag (TBF) reported benefits
- Wound and tissue healing
- Reduced inflammation
- Potential improved tissue penetration vs full TB-4
- Support for tendon and muscle repair
- Angiogenesis promotion
Related comparisons
Research and educational reference only. Not medical advice.